Hansa Biopharma

Hansa Biopharma is a Swedish biopharmaceutical company that develops and commercializes immunomodulatory enzyme therapies for the treatment of rare autoimmune conditions and transplant rejection. The company was founded in 2001 and is headquartered in Lund, Sweden.

Hansa Biopharma's main focus is on the development of therapies that target the immune system to address unmet medical needs in areas such as kidney transplantation, autoimmune disease and antibody-mediated rejection. acute (AMR). Their main product candidate is called imlifidase, formerly known as IdeS. Imlifidase is an enzyme-based treatment designed to selectively cleave antibodies and remove them from the circulation, potentially reducing the risk of rejection in solid organ transplants.

To target pathogenic or pathogenic antibodies, they have created their own patented platform for antibody cleaving enzyme technology. Imlifidase, a first-generation IgG cleavage enzyme, is engineered to inactivate IgG antibodies in tissue and plasma with a single intravenous injection. In transplantation, autoimmunity, gene therapy and cancer, they are actively examining the use of this protein to treat and avoid abnormal diseases caused by IgG antibodies in the acute phase

Founded: 2001

Headquarters: Lund, Sweden

Number of employees: 141

Website: https://www.hansabiopharma.com/